Skip to content

Histological Differentiation Grade Predicted by Ultrasound Backscatterer Imaging

Histological Differentiation Grade Predicted by Ultrasound Backscatterer Imaging

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02786199
Enrollment
100
Registered
2016-05-30
Start date
2015-06-30
Completion date
2018-06-30
Last updated
2016-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplastic Disease, Pathology

Keywords

Hepatocellular Carcinoma(HCC), Ultrasound, Backscatter, Differentiation grade, Survival

Brief summary

Histological grade of hepatocellular carcinoma (HCC) is an important prognostic factor affecting patient survival. It has been divided into four grades from I to IV on the basis of histological differentiation. Grade I is the best differentiated consisting of small tumor cells arranged in thin trabeculae. Cells with higher grade are larger and less differentiated with hyperchromatic nuclei and loss of trabecular pattern. Ultrasound is an imaging modality frequently used to evaluate liver tumors because of its convenience, real-time, less expensive and no radiation exposure. However, ultrasonographic evaluation by conventional B-mode image is semi quantitative and subjective. It still cannot replace liver biopsy for the evaluation of HCC. This study is aimed to quantify the image characters of B-mode image and the scatterer properties using Nakagami distribution. Nakagami parameter is a general model to describe the distribution of scatterers. Therefore, the investigators hypothesized that Nakagami parameter may also reflect the histological changes in different grades of HCC. In this study, the resected HCC tumor samples will be collected from the participants who are going to receive surgical resection, and the tumor US images and Nakagami values will be obtained via the single-element ultrasound system. The correlation between the ultrasound backscatter parameter and the differentiation grade will be analyzed.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 21 to 75 * Patients with HCC who underwent surgery * The resected tumor was measured larger than 3 cm

Exclusion criteria

* Patients who have received other treatment in 6 months * Patients who couldn't regular follow-up

Design outcomes

Primary

MeasureTime frameDescription
Recurrence-free survivalwithin two years after surgerySuspected recurrences will be confirmed by CT or MRI.
Liver-related mortalityfive years

Countries

Taiwan

Contacts

Primary ContactMing-Chih Ho, MD
mcho1215@ntu.edu.tw+886223123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026